Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
Cingulate Inc. Common Stock
CING | US
5.26
USD0.06
1.15%
CING | US
About Cingulate Inc. Common Stock
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
16/04/2026
Close
5.26
Open
5.22
High
5.34
Low
5.08
Cingulate Inc. a clinical-stage biopharmaceutical company focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company's lead product candidates are CTx-1301 (dexmethylphenidate) which is in phase 3 clinical trial and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children adolescents and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City Kansas.
View LessCING | US
Risk
119.4
Sharpe
0.30
Luna's Score
46/100
Recommendation
Hold
Luna says (CING | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
What's not Working
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
41.2%1 month
119.4%3 months
122.3%6 months
97.5%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.53
Debt to equity
0.11
Debt to assets
0.06
Ent. to EBITDA
-0.36
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-18.05M
MarketCap
16.01M
MarketCap(USD)
16.01M
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-1.36K
Short ratio
0.05
Short perc.
0.95
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
1.64
Range1M
6.81
Range3M
7.09
Volumes: Market Activity
Rel. volume
0.50
Price X volume
1.56M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -0.36 | - | Cheaper |
| Ent. to Revenue | - | - | - |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.53 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 122.31 | - | Riskier |
| Debt to Equity | 0.11 | -1.23 | Expensive |
| Debt to Assets | 0.06 | 0.25 | Cheaper |
| Market Cap | 16.01M | - | Emerging |
